Navigation Links
Genome Quebec and Montreal Heart Institute Pharmacogenomics Centre Deploys Isilon IQ in Next Generation of Drug Development

SEATTLE, Oct. 5 /PRNewswire-FirstCall/ -- Isilon® Systems (Nasdaq: ISLN), the proven leader in scale-out NAS, today announced that Pharmacogenomics Centre, a partnership between Genome Quebec and the Montreal Heart Institute focused on enhancing new and existing drug development research programs through the inclusion of genetic information, has deployed Isilon IQ to accelerate its next-generation genetic sequencing operations. In its focused efforts to fight heart disease, cancer and other life-threatening diseases, Pharmacogenomics Centre is leveraging Isilon scale-out NAS to significantly increase workflow efficiency and productivity, while reducing storage management from more than 30 hours per week to less than one hour per week.

"We're sequencing targeted segments of patients' DNA to try and identify individual mutations that can cause those patients to respond unexpectedly to specific drug therapies," said Christopher Beck, senior bioinformatician, Pharmacogenomics Centre. "Obviously the data produced by our next-generation sequencers is mission-critical but we are a scientific organization and our main focus is data analysis, not data storage. We simply can't afford the lengthy storage deployment schedules or complex system management hassles that traditional storage offerings require. With Isilon, we've been able to deploy and manage a high-performance, highly scalable, shared storage resource without having to dedicate any IT staff to managing the system."

With Isilon scale-out NAS, Pharmacogenomics Centre has unified both its DNA sequencing and DNA analysis operations onto a single, shared pool of storage, enabling highly concurrent processing of genomic data to increase productivity and speed time-to-results. Additionally, with Isilon's OneFS® operating system providing 'pay as you grow' scalability, Pharmacogenomics Centre can scale both performance and capacity on-demand to meet the dramatic and unpredictable growth of data within its high-throughput sequencing environment.

"Next-generation genetics research is opening entirely new ways of undertaking critical drug discovery research," said Chris Blessington, senior director of marketing and communications, Isilon Systems. "Pharamcogenomics Centre's successful use of Isilon IQ to advance this new era of drug development is demonstrative of the inherent performance, capacity, and manageability advantages of our scale-out NAS solutions for data-rich life sciences organizations."

About Isilon Systems

Isilon Systems (Nasdaq: ISLN) is the proven leader in scale-out NAS. Isilon's clustered storage and data management solutions drive unique business value for customers by maximizing the performance of their mission-critical applications, workflows, and processes. Isilon enables enterprises and research organizations worldwide to manage large and rapidly growing amounts of file-based data in a highly scalable, easy-to-manage, and cost-effective way. Information about Isilon can be found at

The names of companies mentioned herein are the trademarks of their respective owners.

SOURCE Isilon Systems

SOURCE Isilon Systems
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
2. FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSKs Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
3. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
4. First Jatropha Genome Completed by Synthetic Genomics Inc. and Asiatic Centre for Genome Technology
5. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
6. Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
7. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
8. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
9. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
10. Breakthrough Mapping of Alzheimers Genome Helps ID Four New Suspect Genes
11. Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project
Post Your Comments:
(Date:11/30/2015)... BOCA RATON, Fla. , Nov. 30, ... of Public Research (the Institute) announced today that ... , a medical device start-up company with technology developed ... creation based on publicly-funded research, and bridges early funding ... -based universities and research institutions. ...
(Date:11/30/2015)... Nov. 30, 2015 Baxalta Incorporated ... leader dedicated to delivering transformative therapies to ... conditions, today announced the launch and first ... an extended circulating half-life recombinant factor VIII ... full-length ADVATE [Antihemophilic Factor (Recombinant)]. The treatment ...
(Date:11/30/2015)... Months Ended 30 September 2015 2014RestatedChange%Turnover 545,575 , 518,852 , ... 384,242 , 9.8 Hospital Management Service Income ... (18.3) Medical Insurance Administration Service Income , 2,780 ... and Accessories Sales , 89,645 , 94,580 ... 2,822 , 2,917 , (3.3) Gross ...
Breaking Medicine Technology:
(Date:11/30/2015)... , ... November 30, 2015 , ... Cycling, running, and ... take on extra meaning the morning of February 28, 2016. , That’s when ... Park and thousands will exercise to help children and families at Joe DiMaggio ...
(Date:11/30/2015)... ... November 30, 2015 , ... A ... of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of ... Their study showed that small molecule analogs that target the functions of SecA, ...
(Date:11/30/2015)... ... November 30, 2015 , ... Using a combination of two blood ... children and adults, according to a new study by researchers at the School of ... Children and Adults: Using Combinations of Blood Glucose Tests ,” published in Frontiers in ...
(Date:11/30/2015)... ... November 30, 2015 , ... International telepathology consultations can ... and KingMed Diagnostics researchers. Their review of more than 1,500 pathology ... pathologists resulted in significantly altered treatment plans for more than half of the ...
(Date:11/30/2015)... PHILADELPHIA (PRWEB) , ... November 30, 2015 , ... ... Philadelphia-based non-profit promoting breast and prostate cancer education and prevention—is joining forces with ... evening of philanthropy and Hollywood elegance on December 7, 2015 at the Union ...
Breaking Medicine News(10 mins):